Quintessence Int. 2022 Aug 17;53(8):698-705. doi: 10.3290/j.qi.b3240043.
To systematically evaluate and meta-analyze the short-and long-term clinical and radiologic failure rates of Biodentine versus formocresol as pulpotomy medicaments in primary teeth.
Relevant medical databases were searched until May 2021 for randomized controlled trials that used Biodentine and formocresol as pulpotomy medicaments in primary teeth with deep caries. Primary outcomes included clinical and radiologic failure rates at 12 months. Secondary outcomes were clinical and radiologic failure rates at 3, 6, 9, 13 to 24, and 25 to 48 months.
Nine randomized controlled trials (N = 626) with low risk of bias were included. Pooled analysis showed that compared to formocresol, Biodentine had significantly lower clinical failure rates (relative risk [RR] 0.16; 95% confidence interval (CI) 0.03 to 0.87; six randomized controlled trials; N = 394; GRADE, low) and radiologic failure rates (RR 0.19; 95% CI 0.08 to 0.49; six randomized controlled trials; N = 393; GRADE, low) at 12 months. Radiologic failure rates at 6 and 9 months were significantly lower in the Biodentine group compared to the formocresol group.
Compared to formocresol, Biodentine may be a superior medicament when used for pulpotomy in primary teeth. Adequately powered randomized controlled trials are needed to substantiate this evidence.
系统评价和荟萃分析 Biodentine 与甲醛甲酚作为乳牙活髓切断药物的短期和长期临床及放射学失败率。
检索相关医学数据库，直至 2021 年 5 月，以评估 Biodentine 和甲醛甲酚作为深龋乳牙活髓切断药物的随机对照试验。主要结局包括 12 个月时的临床和放射学失败率。次要结局为 3、6、9、13 至 24 和 25 至 48 个月时的临床和放射学失败率。
纳入 9 项低偏倚风险的随机对照试验（N = 626）。汇总分析显示，与甲醛甲酚相比，Biodentine 的临床失败率（相对风险 [RR] 0.16；95%置信区间 [CI] 0.03 至 0.87；6 项随机对照试验；N = 394；GRADE，低）和放射学失败率（RR 0.19；95%CI 0.08 至 0.49；6 项随机对照试验；N = 393；GRADE，低）均显著降低，差异有统计学意义。12 个月时，Biodentine 组的放射学失败率也显著低于甲醛甲酚组。6 个月和 9 个月时，Biodentine 组的放射学失败率也显著低于甲醛甲酚组。
与甲醛甲酚相比，Biodentine 可能是乳牙活髓切断的一种更优药物。需要进行充分的、以患者为导向的随机对照试验来证实这一证据。
